Hazel Squires BSc (Sheffield), MSc (Lancaster)

HEDS, ScHARR
The University of Sheffield
Regent Court
30 Regent Street
Sheffield
S1 4DA
UK

Office:

Tel: (+44) (0)114 222 0765
Fax: (+44) (0)114 272 4095

E-mail: h.squires@sheffield.ac.uk

Biography

I joined ScHARR in 2005 after completing a BSc in Mathematics from the University of Sheffield and an MSc in Operational Research from Lancaster University. Since joining ScHARR, I have undertaken modelling projects for NICE, the Department of Health, the NHS Cancer Screening Programme and the pharmaceutical industry. A large part of this work has been around cancer screening, diagnosis and treatment. I have also undertaken several cost-effectiveness analyses of public health interventions.

Research interests

• Healthcare modelling
• Discrete event simulation to model healthcare systems
• Modelling within public health
• Methods for handling structural uncertainty

Teaching interests

My teaching interests are:

• Mathematical modelling within healthcare
• Discrete event simulation

http://www.shef.ac.uk/rtpwebsite/unitDetail/3270.html

Professional activities

• Editorial Board of Journal of Simulation
• Member of the General Council and Events Committee of the Operational Research Society

Current projects

I am currently working on the following projects:

• NIHR Fellowship: A methodological framework for developing the structure of public health economic models

Key publications

• Pilgrim H, Chilcott J. Assessment of a 7-day turn-around for the reporting of cervical smear results using discrete event simulation. Journal of the Operational Research Society 2008; 59:902-10.
• Pilgrim H, Tappenden P, Chilcott J, Bending M, Trueman P, Shorthouse A, Tappenden J. The costs and benefits of bowel cancer service developments using discrete event simulation. Journal of the Operational Research Society 2009; 60:1305-14.
• Pilgrim H, Lloyd-Jones M, Rees A. Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation. Health Technology Assessment 2009; 13(10).
• Ward S, Pilgrim H, Hind D, Rees A. Trastuzumab for the treatment of primary breast cancer in HER2 positive women: a single technology appraisal. Health Technology Assessment 2009; 13(1).
• 'Squires, H., Tappenden, P., Cooper, K., Carroll, C., Logan, R., & Hind, D. (2011). Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancer. Clinical Therapeutics, 33(9), 1289-1305